Thousands of oncologists, tens of thousands of samples

Guardant360 is the first comprehensive NGS-based liquid biopsy for advanced cancer. Our 73-gene blood test interrogates all four major types of genomic alterations, and is the only ctDNA test that includes all guideline-recommended somatic genomic targets in a single test.

Guardant360 has undergone extensive analytical and clinical validation and is supported by publications from leading cancer centers globally. It's been used by thousands of oncologists and helps guide treatment decisions at more than 80% of top US cancer centers.

When should you order Guardant360?

Your patient has advanced cancer and is progressing

Tissue is unobtainable or biopsy yields an insufficient quantity for sequencing

Archived biopsies or results are outdated

One or more interventions have occurred since the last biopsy

Rick Lanman, MD
Chief Medical Officer

“Needle biopsies of deep cancers are limited by tumor heterogeneity.”

Becky Nagy, MS LGC
Certified Genetic Counselor

“Liquid biopsy allows you to keep your patients close to home.”

Guardant360 is extensively validated

Guardant360 is the first and only clinically validated comprehensive liquid biopsy available. With 99.9999% specificity, our 73-gene panel looks for alterations across point mutations, amplification, fusions, and indels, including every guideline-recommended somatic alteration.

Based on the tumor genomic profile, we report a list of actionable genomic alterations and the FDA-approved treatments or clinical trials for which the patient could be eligible.

Contraindications for use

Your patient has a hematologic malignancy

Your patient has Stage I or Stage II cancer

Your patient's disease is stable

Your patient is on an active cycle of chemo or radiation therapy

How do we achieve the highest specificity
of any liquid biopsy?

NGS zoom icon

We search for tumor-DNA fragments among billions of cells

NGS zoom icon

We digitally tag each DNA fragment and make millions of copies

NGS zoom icon

Standard sequencing methods introduce errors and false positives

NGS zoom icon

Our digital inference engine reduces these errors by 1000x, enabling near-perfect specificity

Our proprietary digital sequencing technology lets us identify the signal of your patient's individual genomic alterations from the noise of interfering data that is inherent to standard next-generation sequencing techniques. This method gives Guardant360 single-molecule analytical sensitivity and 99.9999% specificity, the highest of any NGS method.

Guardant360 73 Gene Panel
Guardant360 73 Gene Panel

Our case studies

Breast Cancer Lung Cancer Melanoma

Case Studies Diagram

Common Questions

What are genomic alterations and why are they important to cancer?

Genomic alterations are changes that occur within the DNA of cancer cells. Some of these changes accelerate the growth of cancer. Some respond well to specific therapies. With a clear picture of the genomic alterations in your tumor, your doctor may be able to recommend a targeted therapy. In general, targeted therapies have fewer side effects than broad-based chemotherapy. They can also be more selective in stopping the spread of a cancer when other treatments have failed.

How can knowing my cancer's genomic alterations help my treatment?

Some genomic alterations are known to respond better to specific therapies. Guardant360 looks for all these clinically relevant alterations, giving your doctor the opportunity to tailor treatment to your individual cancer.

How quickly can I expect test results?

We provide results within 2 weeks of receiving your blood sample.

Does it matter what type of cancer I have or how advanced my cancer is?

Yes. Guardant360 is only indicated for advanced solid tumors. It does not test for hematological cancers like leukemia, nor early stage disease.

Does Guardant360 predict response to chemotherapy? Can it tell me how my cancer will progress?

Today Guardant360 does not predict chemotherapy response, but it does provide information on the genomic alterations known to respond to specific targeted therapies. As cancer research progresses, new response profiles may be identified.